Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2026

Braganca Xavier Camila, Shah Pooja A, Yakimova Daria, Kravets Andrey, Belousov Dmitrii, Kudryavtseva Ksenia, Massaro Matteo, Paradiso Francesca, Kotlov Nikita, Zhao Dan, Pant Shubham, Hensley Michael, Hong David S, Rodon Jordi

Abstract excerpt

PURPOSE: Comprehensive genomic profiling has prognostic and predictive value for patients with pancreatic adenocarcinoma (PAAD). EXPERIMENTAL DESIGN: We reviewed clinical and molecular data from 4,009 samples from patients who had undergone the BostonGene Tumor Portrait test between October 28, 2021, and October 8, 2024, and 2,181 samples from the BostonGene PAAD meta-cohort, collected from various data hosts and...

Read the complete abstract on PubMed

Topics

Humans
Pancreatic Neoplasms
Purine-Nucleoside Phosphorylase
Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Proto-Oncogene Proteins p21(ras)

Prognosis

Genomics

Biomarkers, Tumor

Adenocarcinoma

Source

Identifiers

PMID: 42240448
DOI: 10.1158/1078-0432.CCR-26-0344

Genes

KRAS
MTAP

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications.PMID 42240448Read ↗

Clinical Significance of MTAP Deletion in Pancreatic Ductal Adenocarcinoma: A Real-World US Patient Cohort StudySemantic proximity Read ↗

Multi-omic characterization reveals a distinct molecular landscape in young-onset pancreatic cancerSemantic proximity Read ↗

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.Semantic proximity Read ↗

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.Semantic proximity Read ↗

Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.Semantic proximity Read ↗

Distinct Mechanisms of Innate and Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with <i>KRAS-TP53</i> Co-Alteration in Pancreatic CancerSemantic proximity Read ↗

Genomic determinants of biological aggressiveness and poor prognosis of pancreatic cancers: KRAS and beyond.Semantic proximity Read ↗

Hypermutation In Pancreatic Cancer.Semantic proximity Read ↗

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessSemantic proximity Read ↗

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathwaySemantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.